Identification of the JNK signaling pathway as a functional target of the tumor suppressor PTEN.

Although most oncogenic phenotypes of PTEN loss are attributed to AKT activation, AKT alone is not sufficient to induce all of the biological activities associated with PTEN inactivation. We searched for additional PTEN-regulated pathways through gene set enrichment analysis (GSEA) and identified genes associated with JNK activation. PTEN null cells exhibit higher JNK activity, and genetic studies demonstrate that JNK functions parallel to and independently of AKT. Furthermore, PTEN deficiency sensitizes cells to JNK inhibition and negative feedback regulation of PI3K was impaired in PTEN null cells. Akt and JNK activation are highly correlated in human prostate cancer. These findings implicate JNK in PI3K-driven cancers and demonstrate the utility of GSEA to identify functional pathways using genetically defined systems.

[1]  T. Golub,et al.  mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways , 2004, Nature Medicine.

[2]  E. Lander,et al.  Reactive oxygen species have a causal role in multiple forms of insulin resistance , 2006, Nature.

[3]  K. Inoki,et al.  TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling , 2002, Nature Cell Biology.

[4]  J. J. Chen,et al.  Profiling the downstream genes of tumor suppressor PTEN in lung cancer cells by complementary DNA microarray. , 2000, American journal of respiratory cell and molecular biology.

[5]  Richard A. Flavell,et al.  The Bax Subfamily of Bcl2-Related Proteins Is Essential for Apoptotic Signal Transduction by c-Jun NH2-Terminal Kinase , 2002, Molecular and Cellular Biology.

[6]  F. Collins,et al.  Transcription factor JunD, deprived of menin, switches from growth suppressor to growth promoter , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[7]  J. Bruce,et al.  Somatic mutations of PTEN in glioblastoma multiforme. , 1997, Cancer research.

[8]  Michael E. Greenberg,et al.  Opposing Effects of ERK and JNK-p38 MAP Kinases on Apoptosis , 1995, Science.

[9]  Gordon B Mills,et al.  mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. , 2006, Cancer research.

[10]  F. Khuri,et al.  Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition. , 2005, Cancer research.

[11]  J. Olefsky,et al.  A rapamycin-sensitive pathway down-regulates insulin signaling via phosphorylation and proteasomal degradation of insulin receptor substrate-1. , 2000, Molecular endocrinology.

[12]  M. Yaniv,et al.  Mouse JunD negatively regulates fibroblast growth and antagonizes transformation by ras , 1994, Cell.

[13]  D. Accili,et al.  Tyrosine Phosphorylation of Insulin Receptor Substrate-1 in Vivo Depends upon the Presence of Its Pleckstrin Homology Region (*) , 1995, The Journal of Biological Chemistry.

[14]  Huajun Yan,et al.  Mammalian target of rapamycin inhibitors activate the AKT kinase in multiple myeloma cells by up-regulating the insulin-like growth factor receptor/insulin receptor substrate-1/phosphatidylinositol 3-kinase cascade , 2005, Molecular Cancer Therapeutics.

[15]  C. Lyle,et al.  Inhibition of Cell Proliferation and Cell Cycle Progression by Specific Inhibition of Basal JNK Activity , 2004, Journal of Biological Chemistry.

[16]  Daniel J. Freeman,et al.  PTEN Deletion Leads to Up-regulation of a Secreted Growth Factor Pleiotrophin* , 2006, Journal of Biological Chemistry.

[17]  M. White,et al.  c-Jun N-terminal Kinase (JNK) Mediates Feedback Inhibition of the Insulin Signaling Cascade* , 2003, The Journal of Biological Chemistry.

[18]  A. Klippel,et al.  Membrane localization of phosphatidylinositol 3-kinase is sufficient to activate multiple signal-transducing kinase pathways , 1996, Molecular and cellular biology.

[19]  S. Morrison,et al.  Pten dependence distinguishes haematopoietic stem cells from leukaemia-initiating cells , 2006, Nature.

[20]  Y. Gotoh,et al.  Three mitogen-activated protein kinases inhibit insulin signaling by different mechanisms in 3T3-L1 adipocytes. , 2003, Molecular endocrinology.

[21]  E. Birney,et al.  Patterns of somatic mutation in human cancer genomes , 2007, Nature.

[22]  M. Wigler,et al.  Design of a retroviral-mediated ecdysone-inducible system and its application to the expression profiling of the PTEN tumor suppressor , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[23]  Chaohong Sun,et al.  Aminopyridine-based c-Jun N-terminal kinase inhibitors with cellular activity and minimal cross-kinase activity. , 2006, Journal of medicinal chemistry.

[24]  R. Mamillapalli,et al.  Genetic deletion of the Pten tumor suppressor gene promotes cell motility by activation of Rac1 and Cdc42 GTPases , 2000, Current Biology.

[25]  F. Christians,et al.  PTEN Expression Causes Feedback Upregulation of Insulin Receptor Substrate 2 , 2001, Molecular and Cellular Biology.

[26]  C. Rondinone,et al.  Serine/threonine phosphorylation of IRS-1 triggers its degradation: possible regulation by tyrosine phosphorylation. , 2001, Diabetes.

[27]  B. Foster,et al.  Characterization of prostatic epithelial cell lines derived from transgenic adenocarcinoma of the mouse prostate (TRAMP) model. , 1997, Cancer research.

[28]  A. Manning,et al.  Targeting JNK for therapeutic benefit: from junk to gold? , 2003, Nature Reviews Drug Discovery.

[29]  S. Lowe,et al.  Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy , 2004, Nature.

[30]  A. Kral,et al.  Identification and characterization of pleckstrin-homology-domain-dependent and isoenzyme-specific Akt inhibitors , 2022 .

[31]  Hong Wu,et al.  Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[32]  W. Hahn,et al.  Human mammary epithelial cell transformation through the activation of phosphatidylinositol 3-kinase. , 2003, Cancer cell.

[33]  T. Hambuch,et al.  The Bcr-Abl leukemia oncogene activates Jun kinase and requires Jun for transformation. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[34]  J. Schlessinger,et al.  Activation of the JNK pathway is essential for transformation by the Met oncogene , 1997, The EMBO journal.

[35]  M E Greenberg,et al.  A cytoplasmic inhibitor of the JNK signal transduction pathway. , 1997, Science.

[36]  K. Petersen,et al.  Impaired mitochondrial activity in the insulin-resistant offspring of patients with type 2 diabetes. , 2004, The New England journal of medicine.

[37]  T. Golub,et al.  Molecular profiling of diffuse large B-cell lymphoma identifies robust subtypes including one characterized by host inflammatory response. , 2004, Blood.

[38]  R. Davis,et al.  Signal Transduction by the JNK Group of MAP Kinases , 2000, Cell.

[39]  M. Kracht,et al.  Inducible Expression of a Constitutively Active Mutant of Mitogen-activated Protein Kinase Kinase 7 Specifically Activates c-JUN NH2-terminal Protein Kinase, Alters Expression of at Least Nine Genes, and Inhibits Cell Proliferation* , 2002, The Journal of Biological Chemistry.

[40]  Todd R. Golub,et al.  Prostate intraepithelial neoplasia induced by prostate restricted Akt activation: The MPAKT model , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[41]  A. Coulson,et al.  A functional genomic analysis of cell morphology using RNA interference , 2003, Journal of biology.

[42]  D. Geschwind,et al.  PTEN negatively regulates neural stem cell self-renewal by modulating G0-G1 cell cycle entry. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[43]  R. Flavell,et al.  JunD mediates survival signaling by the JNK signal transduction pathway. , 2003, Molecular cell.

[44]  M. Daly,et al.  PGC-1α-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes , 2003, Nature Genetics.

[45]  P. Houghton,et al.  IRS-1: auditing the effectiveness of mTOR inhibitors. , 2006, Cancer cell.

[46]  Zhijian Zhao,et al.  Discovery of 2,3,5-trisubstituted pyridine derivatives as potent Akt1 and Akt2 dual inhibitors. , 2005, Bioorganic & medicinal chemistry letters.

[47]  Mehdi Tnani,et al.  Elevated JNK activation contributes to the pathogenesis of human brain tumors , 2002, Oncogene.

[48]  J. Blenis,et al.  An inhibitor of mTOR reduces neoplasia and normalizes p70/S6 kinase activity in Pten+/− mice , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[49]  C. Sawyers,et al.  The phosphatidylinositol 3-Kinase–AKT pathway in human cancer , 2002, Nature Reviews Cancer.

[50]  P. Nelson,et al.  Prostate-specific deletion of the murine Pten tumor suppressor gene leads to metastatic prostate cancer. , 2003, Cancer cell.

[51]  Y. Le Marchand-Brustel,et al.  Positive and negative regulation of insulin signaling through IRS-1 phosphorylation. , 2005, Biochimie.

[52]  Michael Karin,et al.  A central role for JNK in obesity and insulin resistance , 2002, Nature.

[53]  P. Pandolfi,et al.  Pten Dose Dictates Cancer Progression in the Prostate , 2003, PLoS biology.

[54]  M. Berger,et al.  Akt pathway activation converts anaplastic astrocytoma to glioblastoma multiforme in a human astrocyte model of glioma. , 2001, Cancer research.

[55]  Peter Angel,et al.  The jun proto-oncogene is positively autoregulated by its product, Jun/AP-1 , 1988, Cell.

[56]  Richard A. Flavell,et al.  Survival signaling mediated by c-Jun NH2-terminal kinase in transformed B lymphoblasts , 2002, Nature Genetics.

[57]  D. Pfaff,et al.  Inhibition of neuronal phenotype by PTEN in PC12 cells. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[58]  Hong Wu,et al.  PTEN tumor suppressor regulates p53 protein levels and activity through phosphatase-dependent and -independent mechanisms. , 2003, Cancer cell.

[59]  Pablo Tamayo,et al.  Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[60]  S. Sciacchitano,et al.  Different subcellular localization and phosphoinositides binding of insulin receptor substrate protein pleckstrin homology domains. , 2000, Molecular endocrinology.

[61]  A. Satterthwaite,et al.  Activation of Bruton's tyrosine kinase (BTK) by a point mutation in its pleckstrin homology (PH) domain. , 1995, Immunity.